Sign in

    Keay Thomas Nakae

    Senior Research Analyst at Chardan Capital Markets, LLC

    Keay Thomas Nakae is a Senior Research Analyst at Chardan Capital Markets specializing in healthcare equity research, with extensive coverage of biotechnology, pharmaceutical, and medical device companies including Arrowhead Pharmaceuticals, Monopar Therapeutics, Orchestra BioMed, Korro Bio, Coya Therapeutics, and Arbutus Biopharma. He is regularly recognized for his analytical acumen, having been featured in Forbes’ America’s Best Analysts rankings and cited across top financial media. Nakae began his analyst career over 17 years ago, holding roles at Wedbush Morgan, CE Unterberg Towbin/Collins Stewart, and Ascendiant Capital Markets prior to joining Chardan in January 2015. He holds an MBA from UCLA Anderson, MS and BS degrees in electronic engineering from Cal Poly San Luis Obispo, is a CFA charterholder, and is also FINRA registered.

    Keay Thomas Nakae's questions to STEM (STEM) leadership

    Keay Thomas Nakae's questions to STEM (STEM) leadership • Q1 2015

    Question

    Keay Thomas Nakae from Chardan Capital Markets, LLC inquired about the specific mechanisms of the company's stem cells in dry AMD, the reasons for the Phase II trial's delay, potential protocol changes like increasing sample size, the number of participating trial sites, and the completeness of patient follow-up data for the upcoming ISSCR presentation.

    Answer

    Chief Medical Officer Dr. Stephen Huhn detailed that the cells likely have a multi-factorial mechanism, including phagocytosis and secreting trophic factors to support photoreceptors. He attributed the trial delay to careful protocol planning and confirmed the design includes an interim analysis to potentially adjust sample size. CEO Martin M. McGlynn and Dr. Huhn confirmed approximately 21 sites are planned and that full 12-month follow-up data would be analyzed for the ISSCR presentation.

    Ask Fintool Equity Research AI